| Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1057 | 2019 |
| A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 1021 | 2011 |
| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 471 | 2015 |
| Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children … A Bonaventure, R Harewood, CA Stiller, G Gatta, J Clavel, DC Stefan, ... The Lancet Haematology 4 (5), e202-e217, 2017 | 223 | 2017 |
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ... Clinical Cancer Research 18 (9), 2515-2525, 2012 | 217 | 2012 |
| Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022 | 215 | 2022 |
| High-dose vitamin C enhances cancer immunotherapy A Magrì, G Germano, A Lorenzato, S Lamba, R Chilà, M Montone, ... Science translational medicine 12 (532), eaay8707, 2020 | 192 | 2020 |
| MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors P Luraghi, G Reato, E Cipriano, F Sassi, F Orzan, V Bigatto, F De Bacco, ... Cancer research 74 (6), 1857-1869, 2014 | 151 | 2014 |
| Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry F Sassi, C Benazzi, G Castellani, G Sarli BMC Veterinary Research 6, 1-9, 2010 | 143 | 2010 |
| The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2) M Matz, MP Coleman, M Sant, MD Chirlaque, O Visser, M Gore, ... Gynecologic oncology 144 (2), 405-413, 2017 | 142 | 2017 |
| Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations F Galimi, D Torti, F Sassi, C Isella, D Corà, S Gastaldi, D Ribero, ... Clinical cancer research 17 (10), 3146-3156, 2011 | 140 | 2011 |
| Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2) M Matz, MP Coleman, H Carreira, D Salmerón, MD Chirlaque, C Allemani, ... Gynecologic oncology 144 (2), 396-404, 2017 | 138 | 2017 |
| IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies ER Zanella, F Galimi, F Sassi, G Migliardi, F Cottino, SM Leto, B Lupo, ... Science translational medicine 7 (272), 272ra12-272ra12, 2015 | 117 | 2015 |
| Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas SM Leto, F Sassi, I Catalano, V Torri, G Migliardi, ER Zanella, M Throsby, ... Clinical Cancer Research 21 (24), 5519-5531, 2015 | 109 | 2015 |
| Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling B Ponsioen, JB Post, JR Buissant des Amorie, D Laskaris, RL van Ineveld, ... Nature cell biology 23 (4), 377-390, 2021 | 89 | 2021 |
| Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas D Sangiolo, G Mesiano, L Gammaitoni, V Leuci, M Todorovic, L Giraudo, ... Cancer research 74 (1), 119-129, 2014 | 86 | 2014 |
| Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer S Gastaldi, F Sassi, P Accornero, D Torti, F Galimi, G Migliardi, ... Oncogene 32 (11), 1428-1440, 2013 | 76 | 2013 |
| Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer M Clemente, AR Sánchez-Archidona, D Sardón, L Díez, A Martín-Ruiz, ... The Veterinary Journal 197 (2), 427-432, 2013 | 71 | 2013 |
| Molecular pathways: sensitivity and resistance to anti-EGFR antibodies A Bertotti, F Sassi Clinical Cancer Research 21 (15), 3377-3383, 2015 | 52 | 2015 |
| Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation G Cavalloni, C Peraldo-Neia, F Sassi, G Chiorino, I Sarotto, M Aglietta, ... Bmc Cancer 16, 1-11, 2016 | 43 | 2016 |
